Results 51 to 60 of about 35,587 (246)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma

Cells, 2021
Since the initial discovery of recurrent isocitrate dehydrogenase 1 (IDH1) mutations at Arg132 in glioma, IDH1 hotspot mutations have been identified in cholangiocarcinoma, chondrosarcoma, leukemia, and various other types of cancer of sporadic incidence.
Balazs Murnyak, L. Eric Huang
doaj   +1 more source

Multi‐Omics Integration for Advancing Glioma Precision Medicine

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However,
Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro   +4 more
wiley   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

Advanced Science, EarlyView.
IDH‐mutant gliomas exhibit sensitivity to PARP inhibitors (PARPi) owing to oncometabolite 2‐HG‐induced DNA repair defects. PARPi treatment induces resistance by upregulating Prickle4, which promotes VEGF‐driven angiogenesis. Combining PARPi veliparib with anti‐angiogenic lenvatinib blocks this pathway, causing tumor regression and prolonged survival in
Ju Yang, Hua Yang, Yifan Yuan, Chenyang Zhang, Ziwei Fu, Yanyan Chen, Yinghong Xiong, Shuyu Chen, Kexin Ling, Ying Liu, Jason T. Huse, Bo Chen, Timothy A. Chan, Zengxin Qi, Zhao Zhang, Xiuping Liu, Yuxiang Wang   +16 more
wiley   +1 more source

Geometrically Encoded Positioning of Introns, Intergenic Segments, and Exons in the Human Genome

Advanced Science, EarlyView.
This study introduces a new hypothesis: exons, introns, and intergenic segments are non‐random projections of the functional layers of 3D structure of chromatin packing domains. Evidence is presented that this “geometric code” may encode volumetric structure, reconciling epigenetic patterns, correlates with oncogenic mutations, acting as a potential ...
Luay M. Almassalha, Kyle L. MacQuarrie, Marcelo Carignano, Cody L. Dunton, Ruyi Gong, Joe Ibarra, Lucas M. Carter, Wing Shun Li, Rikkert Nap, Parambir S. Dulai, Igal Szleifer, Vadim Backman   +11 more
wiley   +1 more source

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells

Cell Reports, 2018
Summary: Neomorphic mutations in NADP-dependent isocitrate dehydrogenases (IDH1 and IDH2) contribute to tumorigenesis in several cancers. Although significant research has focused on the hypermethylation phenotypes associated with (D)2-hydroxyglutarate ...
Mehmet G. Badur, Thangaselvam Muthusamy, Seth J. Parker, Shenghong Ma, Samuel K. McBrayer, Thekla Cordes, Jose H. Magana, Kun-Liang Guan, Christian M. Metallo   +8 more
doaj   +1 more source

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer

Acta Pharmaceutica Sinica B, 2023
Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy. Isocitrate dehydrogenases (IDHs) are a class of key proteins in energy metabolism, including IDH1, IDH2 ...
Yang Liu, Wei Xu, Mingxue Li, Yueying Yang, Dejuan Sun, Lidian Chen, Hua Li, Lixia Chen   +7 more
doaj   +1 more source

KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

Advanced Science, EarlyView.
Cholangiocarcinoma (CCA) driven by oncogenic KRAS depends on its continuous activation for tumor maintenance. Using a conditional KRAS model, the authors show that turning off KRAS triggers rapid tumor regression accompanied by immune cell infiltration and cytokine release. The findings uncover a KRAS–senescence–immune signaling axis and highlight KRAS
Youwei Qiao, Matthew F. Yee, Chaitanya N. Parikh, Boyang Ma, Yueying Cao, Yu‐Huan Shih, Joae Qiong Wu, Marcus Ruscetti, Shun‐Qing Liang, Wen Xue   +9 more
wiley   +1 more source

Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. [PDF]

PLoS ONE, 2015
Glioblastoma can occur either de novo or by the transformation of a low grade tumour; the majority of which harbor a mutation in isocitrate dehydrogenase (IDH1). Anaplastic tumours are high-grade gliomas that may represent the final step in the evolution
Jason K Wasserman, Garth Nicholas, Rebecca Yaworski, Anne-Marie Wasserman, John M Woulfe, Gerard H Jansen, Santanu Chakraborty, Thanh B Nguyen   +7 more
doaj   +1 more source

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability [PDF]

, 2022
Danièl Thomas, Manhong Wu, Yusuke Nakauchi, Ming Zheng, Chloe Thompson-Peach, Kelly Lim, Niklas Landberg, Thomas Köhnke, Nirmal Robinson, Satinder Kaur, Monika Kutyna, Melissa Stafford, Devendra Hiwase, Andreas Reinisch, Gary Peltz, Ravindra Majeti   +15 more
openalex   +1 more source